Abstract

The P23H variant of rhodopsin results in misfolding of the protein, and is a common cause of the blinding disease autosomal dominant retinitis pigmentosa (adRP). We have recently demonstrated that degeneration of photoreceptor cells in retinas of P23H mice is due to the endoplasmic reticulum stress (ERS)-induced activation of autophagy that leads to a secondary proteasome insufficiency and activation of cell death pathways. We propose that this increased level of autophagy flux relative to proteasome activity, which we term the A:P ratio, represents a marker of altered photoreceptor cell homeostasis, and that therapies aimed at normalizing this ratio will result in increased photoreceptor cell survival. To test this postulate, we treated P23H mice with a chemical chaperone (4-phenylbutyric acid) to improve rhodopsin folding, or with a selective phosphodiesterase-4 inhibitor (rolipram) to increase proteasome activity. P23H mice treated with either of these agents exhibited reduced ERS, decreased autophagy flux, increased proteasome activity, and decreased activation of cell death pathways. In addition, rates of retinal degeneration were decreased, and photoreceptor morphology and visual function were preserved. These findings support the conclusion that normalizing the A:P ratio, either by reducing the ERS-induced activation of autophagy, or by increasing proteasome activity, improves photoreceptor survival, and suggest a potential new therapeutic strategy for the treatment of adRP caused by protein folding defects.

Highlights

  • Inherited retinal degeneration (IRD) occurs in ~1 in 3000 people in the population and results from mutations in nearly 300 different genes[1,2]

  • To test the hypothesis that normalizing the A:P ratio results in decreased activation of cell death pathways and increased photoreceptor function, our studies focused on the produce RhoP23H/+ mice (P23H) mouse model of proteotoxic cell death

  • We began by evaluating whether improved folding and trafficking of P23H to the proteasome would result in decreased endoplasmic reticulum stress (ERS) and autophagy activation

Read more

Summary

Introduction

Inherited retinal degeneration (IRD) occurs in ~1 in 3000 people in the population and results from mutations in nearly 300 different genes[1,2]. This extreme genetic heterogeneity has complicated the development of therapies for individuals with IRD. There is an unmet need for therapies that target broadly shared pathophysiological mechanisms and that achieve lasting rescue in a mutation-independent manner. Mutations in the rhodopsin gene RHO, a common cause of IRD, often lead to misfolding or mistrafficking of the rhodopsin protein, resulting in proteotoxicity[4]. A mutation that results in the substitution of histidine for proline at amino acid residue 23 of rhodopsin

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call